Stryker Corporation (SYK)
- Previous Close
327.68 - Open
328.55 - Bid 334.08 x 1200
- Ask 334.28 x 900
- Day's Range
327.20 - 335.11 - 52 Week Range
249.98 - 361.41 - Volume
1,144,215 - Avg. Volume
1,255,040 - Market Cap (intraday)
127.454B - Beta (5Y Monthly) 0.91
- PE Ratio (TTM)
40.56 - EPS (TTM)
8.26 - Earnings Date Apr 30, 2024
- Forward Dividend & Yield 3.20 (0.98%)
- Ex-Dividend Date Mar 27, 2024
- 1y Target Est
372.04
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
www.stryker.comRecent News: SYK
Performance Overview: SYK
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SYK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SYK
Valuation Measures
Market Cap
124.67B
Enterprise Value
134.61B
Trailing P/E
39.72
Forward P/E
27.62
PEG Ratio (5yr expected)
2.79
Price/Sales (ttm)
6.13
Price/Book (mrq)
6.71
Enterprise Value/Revenue
6.57
Enterprise Value/EBITDA
27.28
Financial Highlights
Profitability and Income Statement
Profit Margin
15.44%
Return on Assets (ttm)
6.87%
Return on Equity (ttm)
17.98%
Revenue (ttm)
20.5B
Net Income Avi to Common (ttm)
3.16B
Diluted EPS (ttm)
8.26
Balance Sheet and Cash Flow
Total Cash (mrq)
3.05B
Total Debt/Equity (mrq)
72.58%
Levered Free Cash Flow (ttm)
2.65B
Research Analysis: SYK
Company Insights: SYK
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: SYK
The Argus Innovation Model Portfolio
The United States economy is full of innovation. It has to be. Manufacturing industries that dominated the economy decades ago - textiles, televisions, even automobiles to a large degree - have moved overseas, where labor and materials costs are lower. Yet the U.S. economy, even during the pandemic and the current period of high inflation, has expanded to record levels. If U.S. corporations weren't innovating, creating new products (such as vaccines and AI) and services (such as Zoom calls) and moving into new markets, the domestic economy would not be growing, and capital would not be flooding into the country. The current high level of the U.S. dollar relative to currencies around the world attests to the confidence that global investors have in the durable and innovative U.S. economy.
Weekly Stock List
We see what we believe are some great opportunities right now in Healthcare -- and we like the sector overall. Argus Director of Research Jim Kelleher, CFA, recently completed his quarterly sector review and raised Healthcare sector to Over-Weight from Market-Weight. The healthcare environment is undergoing rapid transitions, and we now see an unfolding period of significant promise and opportunity. Our newly-favored stance is based on resumption of deferred medical procedures and significant new quality-of-life drugs and treatments. The category is broad and has underperformed the S&P 500 over the past year. The Healthcare sector ETF (XLV) is up 15% over the past year compared to a gain of 31% for the S&P 500. We see opportunity here to pick up some steady companies, with big brands and solid financials. These companies are science-focused and enhance lives. They are innovators. In our list this week, we look across several subsectors within the Healthcare sector and pull out some leaders we like. These stocks also are included in our Focus List and Model Portfolios, as noted below.
Analyst Report: Stryker Corp.
Based in Kalamazoo, Michigan, Stryker manufactures and markets medical devices, primarily in the orthopedic market. The Orthopedics segment sells joint reconstructive products (hips, knees and shoulders) and trauma implants. The MedSurg Equipment segment sells powered surgical instruments, surgical navigation systems, endoscopic products, medical video imaging equipment, and hospital beds and patient-handling systems. The Neurotechnology unit includes the neurovascular business as well as the interventional spine and spinal implants business.
RatingPrice TargetMarket Digest: CHD, OGE, PWR, SYK, WWW, WRK, NET
Nearly two months into 2024, stocks continue to perform well, yet insiders remain very cautious (as they have been for the past month). Insiders have unique views into their respective corners of the market, and their overt caution begs a question. Shouldn't stocks be pulling back if insiders are correct?